Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
DALLAS and FORT WORTH, Texas, March 08, 2016 -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing and commercializing innovative extended-release (XR) products for the treatment of attention-deficit/hyperactivity disorder (ADHD), today announced that it will report financial results for the fourth quarter and fiscal year ended December 31, 2015 before the market opens on Thursday, March 17, 2016. Management will host a conference call beginning at 8:30 a.m. Eastern Time that day to review results and provide a company update.
To access the call, dial 866-842-7969 (U.S.) or 704-908-0466 (outside of the U.S.). The Conference ID is 67016685. A live webcast will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/. Please log in approximately 5-10 minutes prior to the scheduled start time.
The archived webcast will be available on the company’s Investor Relations page under Presentations.
About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified‐release drug delivery technology platforms. The Company recently received FDA approval of Adzenys XR-ODT™ - the first and only FDA-approved amphetamine extended-release orally disintegrating tablet for the treatment of ADHD. Neos has two other branded product candidates in development, an XR-ODT of methylphenidate and a liquid suspension of amphetamine for the treatment of ADHD. In addition, Neos manufactures and markets its generic equivalent of the branded product Tussionex®1, an XR liquid suspension of hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a cold.
1Tussionex® is a registered trademark of the UCB Group of Companies
CONTACTS: Richard I. Eisenstadt Chief Financial Officer Neos Therapeutics (972) 408‐1389 [email protected] David Carey, Investor Relations Lazar Partners (212) 867‐1768 [email protected]
